Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the drug, called AEG35156, can be safely given
to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the
sensitivity of cancer cells to chemotherapy (ara-C and idarubicin) in patients with
refractory or relapsed AML.